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The structure and regulation of Cullin 2 
based E3 ubiquitin ligases and their biological 
functions
Weijia Cai* and Haifeng Yang* 
Abstract 
Background: Cullin-RING E3 ubiquitin ligase complexes play a central role in targeting cellular proteins for ubiquit-
ination-dependent protein turnover through 26S proteasome. Cullin-2 is a member of the Cullin family, and it serves 
as a scaffold protein for Elongin B and C, Rbx1 and various substrate recognition receptors to form E3 ubiquitin ligases.
Main body of the abstract: First, the composition, structure and the regulation of Cullin-2 based E3 ubiquitin ligases 
were introduced. Then the targets, the biological functions of complexes that use VHL, Lrr-1, Fem1b, Prame, Zyg-11, 
BAF250, Rack1 as substrate targeting subunits were described, and their involvement in diseases was discussed. A 
small molecule inhibitor of Cullins as a potential anti-cancer drug was introduced. Furthermore, proteins with VHL box 
that might bind to Cullin-2 were described. Finally, how different viral proteins form E3 ubiquitin ligase complexes 
with Cullin-2 to counter host viral defense were explained.
Conclusions: Cullin-2 based E3 ubiquitin ligases, using many different substrate recognition receptors, recognize a 
number of substrates and regulate their protein stability. These complexes play critical roles in biological processes 
and diseases such as cancer, germline differentiation and viral defense. Through the better understanding of their 
biology, we can devise and develop new therapeutic strategies to treat cancers, inherited diseases and viral infections.
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Background
Cullin-RING E3 ubiquitin ligase complexes (CRLs) play 
a central role in targeting cellular proteins for ubiquit-
ination-dependent protein turnover through 26S pro-
teasome [1]. Cullin-2 (Cul2), a member of Cullin family 
proteins, is encoded by CUL2. Cul2 functions as a scaf-
fold protein to form CRLs that belong to the Elongin B 
and C-Cul2 or Cul5-SOCS box protein (ECS) family [2]. 
In CRL2 complexes, Cul2 assembles with RING protein 
(Rbx1) (also known as Roc1) as RING finger protein, 
Elongin B and C proteins as adapter proteins and various 
substrate recognition receptors [2, 3].
Cul2 is different from other most Cullins, which are 
evolutionarily conserved from yeast to human. Cul2 
is present only in multi-cellular organisms and plays 
a particular function [4]. The most well-known CRL2 
substrate recognition receptor is the tumor suppres-
sor protein VHL that is mutated in von Hippel–Lindau 
(VHL) syndrome, a rare hereditary cancer syndrome [5]. 
Germline VHL mutations usually disrupt the interac-
tion between VHL and Elongin B and C, and inactivate 
the VHL-Elongin B/C-Cullin-2 E3 ligase [6]. CRL2VHL 
complex-dependent degradation of the α subunits of 
hypoxia inducible factor (HIFα) is the most studied role 
of CRL2 ubiquitin ligase in tumorigenesis [7, 8]. In addi-
tion, CRL2 ligases are involved in other cellular processes 
including germline development and viral infection. This 
review will go over the structure and regulations of CRL2 
ligases, their substrate recognition receptors and their 
numerous substrates, and discuss their involvement in 
biological processes and diseases.
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Main text
Structure and regulation
Similar to other Cullins, Cul2 contains an evolutionary 
conserved Cullin homology (CH) domain at its C-ter-
minus. The CH domain was found to interact with Rbx1, 
which further recruits E2 ubiquitin conjugating enzymes 
[9] (Fig. 1). The N-terminus of Cul2 was responsible for 
interacting with Elongin B and C and various substrate 
recognition receptors (Fig.  1). These receptors usually 
contained a special domain called VHL-box [10].
Elongin B and C proteins were originally found as two 
regulatory subunits of the Elongin complex, which was a 
positive regulator of RNA polymerase II and increased 
the rate of mRNA elongation by suppressing transient 
pausing along the DNA template. Elongin B and C bound 
to each other and enhanced the transcriptional activity of 
the other component of Elongin complex, Elongin A [4–
6]. Elongin B and C were later found to bind to Cul2 or 
Cullin-5 (Cul5) and serve as adapter components of ECS 
ubiquitin ligases [11–13].
VHL and other Cul2-Rbx1 interacting proteins such 
as Leucine-Rich Repeat protein-1 (LRR-1) and Femini-
zation-1 (FEM-1) have a region of homology called the 
VHL box (Fig. 2). This box contained both a BC box [14] 
(consensus sequence: (S,T,P)LXXX(C,S,A)XXXф, with 
ф meaning a hydrophobic amino acid), which bound to 
Elongin B and C, and a Cullin 2 box (consensus sequence: 
фPXXфXXXф), which was responsible for binding to 
Cul2. Detailed alignment that defined VHL box could 
be found in Mahrour et al. [10]. VHL box was very simi-
lar to Suppressor Of Cytokine Signaling (SOCS) box, 
which also contained a BC box and a Cullin 5 box (Fig. 2). 
Although both VHL box proteins and SOCS box proteins 
used Elongin B and C as an adaptor, they bound to dif-
ferent Cullins. The different Cullin boxes determined the 
binding specificity to Cul2 and Cul5 [14–16].
A recent paper described the crystal structure of a 
CRL2 complex composed of VHL, Elongin B and C and 
the N-terminus of Cul2 [17]. It showed that in many 
ways CRL2 structure were different from these of CRL1 
or CRL5 complex. The CRL2 complex assumed a tripod 
shape, with Elongin C located in the center and the other 
components at the ends. Cul2 bound to the interface 
between VHL and Elongin C through hydrophobic and 
electrostatic interactions. Cul2 binding induced a struc-
turing of Elongin C loop (residue 48–57) which made 
contact with Cul2. The same loop was not structured 
in the VHL-Elongin BC complex [18]. Different from 
Cul5, the N-terminal extension of Cul2 played a critical 
role in binding to Elongin C. For example, residue L3 of 
Cul2 inserted into a hydrophobic pocket of Elongin C. 
L3G mutant of Cul2 drastically reduced the interaction 
between Cul2 and VHL-Elongin BC complex. Consist-
ently, the N-terminal extension was highly conserved 
across all Cullin-2 orthologs. Importantly, not only the 
Cullin 2 box was critical for Cul2-VHL interaction [16], 
the BC box on VHL also made critical contact with Cul2 
via hydrogen bonds and salt bridge interactions [17].
Similar to other Cullin family members, Cul2 con-
tained a neddylation site close to the RING protein 
Fig. 1 Structure of CRL2VHL complex and Nedd8-mediated regula-
tion of CRL2 activity. Cul2 is the scaffold protein that binds to Rbx1, 
Elongin C and VHL directly. Neddylation on lysine 689 of cullin-2 
dissociates Cand1, which allows the Cul2 to bind to Elongin B, C and 
VHL, facilitates appropriate conformation of Rbx1 and promotes ubiq-
uitination on substrate proteins. Ube2m promotes neddylation of 
Cul2 and increases CRL2 activity, whereas CSN5 and inhibitor inhibit 
CRL2 activity. Ub ubiquitin, N Nedd8
Fig. 2 The compositions of VHL box and SOCS box. VHL box is made 
up of a BC box and a Cullin2 box. SOCS box consists of a BC box and 
a Cullin5 box
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(Rbx1) binding site [19]. Auto-neddylation of Cullin by 
Rbx1 induced conformational change at C-terminus, 
resulting in stabilization of an optimal Rbx1 position 
and activation of CRL ubiquitin transfer activity [20–
22]. NEDD8-conjugating enzyme Ube2m (also known 
as Ubc12) promoted neddylation of Cullin 1-4 through 
Rbx1, whereas Ube2f neddylated Cullin 5 through Rbx2 
[23]. Conversely, deneddylation by COP9 signalosome 
complex subunit 5 (Csn5) or a small molecule inhibitor of 
NEDD8-activating enzyme (MLN4924) [24] led to bind-
ing of Cullin-Associated and Neddylation-Dissociated 1 
(Cand1) to Cullins. This binding sterically inhibited the 
interaction between Cullin and adaptor proteins, and 
impaired Rbx1-mediated E2 ubiquitin activation [24–30] 
(Fig.  1). Interestingly, engagement of substrates to CRL 
complex could induce Cullin neddylation [31, 32]. This 
‘substrate-mediated neddylation’ was recently reported to 
be mediated by Defective in Cullin Neddylation 1 (Dcnl1) 
[33]. Dcnl1 was the human homolog of Dcn1 in Saccha-
romyces cerevisiae, also known as Sccro or Dcun1d1, 
which was an E3 Nedd8 ligase that promoted Cullin 
neddylation with Rbx1 [34–37]. Interaction between 
VHL and its substrate HIF1α promoted the recruitment 
of Dcnl1 to trigger Cul2 neddylation, and consequently 
HIF1α ubiquitination and proteasomal degradation [33].
Different CRL2 E3 ubiquitin ligase complexes
There are a number of CRL2 complexes that are con-
firmed as functional E3 ubiquitin ligases. They can be 
divided into two groups: cellular CRL2 complexes that 
are derived from cellular proteins, and viral CRL2 com-
plexes that contain viral proteins. Known CRL2 E3 com-
plex and their substrates are summarized in Table 1.
CRL2VHL complex
Von Hippel–Lindau (VHL) syndrome was first described 
separately by von Hippel in 1911 and by Lindau in 1926 
[5]. It was characterized by the development of multi-
ple vascular tumors and was caused by a mutation of 
both alleles of the VHL gene located on the short arm of 
chromosome 3 [38]. VHL was a 213 amino acid protein 
product of the VHL tumor suppressor gene. Most ger-
mline VHL mutations were missense alterations that pro-
duced mutated VHL proteins that lost ability to bind to 
Elongin B and C [39, 40]. Further study showed that VHL 
formed a complex with Cul2, Elongin B and C and Rbx1, 
and had E3 ubiquitin ligase activity [6, 9, 41]. The CRL2 
ligase complex could bind to HIFα through the β domain 
of VHL, promote ubiquitination and proteasomal degra-
dation of HIFα [42, 43]. HIFα family consisted of three 
members, HIF1α, HIF2α and HIF3α. They were unstable 
subunit of HIF complex, and formed the HIF transcrip-
tional factor with constitutively expressed HIF1β, also 
called Aryl Hydrocarbon Receptor Nuclear Translocator 
(ARNT), to regulate gene expressions [7]. HIF down-
stream target genes [44] include vascular endothelial 
growth factor A (VEGFA) [45, 46], solute carrier family 2 
member 1 (SLC2A1, which was also called GLUT1), and 
platelet-derived growth factor-β (PDGFB) [47], which 
were known to drive cell growth and proliferation of 
microvascular vessels in VHL syndrome [42].
The HIF transcriptional activity is tightly regulated 
by oxygen concentration. Under normal oxygen ten-
sion (normoxia), two key proline residues in the oxy-
gen-dependent degradation domain of HIFα were 
hydroxylated by HIF prolyl hydroxylases (PHD1–3). 
Hydroxylated HIFα provided a binding signal for the 
β-domain of VHL [43, 48–53]. Consequently HIFα was 
poly-ubiquitinated by CRL2VHL E3 ubiquitin ligase and 
degraded by the proteasome. When oxygen was taken 
away (hypoxia), HIFα was produced but not hydroxylated 
Table 1 Known CRL2 complexes and their substrates
Ubiquitin  
ligase
Interaction 
domain
Substrates Reference
VHL VHL box HIFα [1–5]
Spry2 [6]
Rpb1 [7, 8]
Rpb7 [9]
Atypical PKC  
(PKCλ and ζII)
[10, 11]
EGFR [12]
LRR-1 VHL box CKI-1 (C. elegans) [13–15]
p21CIP [15]
HTP3 (C. elegans) [16]
FEM1/Fem1B VHL box TRA-1(C. elegans) [17]
Gli1 [18]
Ankrd37 (mouse) [19]
Prame VHL box unknown [20, 21]
ZYG-11/ZER1 VHL box unknown [22, 23]
BAF250/Osa/
BAF250b
BC box H2B [24]
Rack1 BC box-like HIF-1α [25]
BimEL [26]
Ad E4orf6 BC box p53 [27–30]
Mre11 [29–31]
DNA ligase IV [29, 30, 32]
Intergrin α3 [29, 30, 33]
TOPBP1 [29, 34]
EBV Bzlf1 Cul2 box p53 [35–37]
HPV16 E7 incomplete 
Cul2 box
pRB [38–41]
BIV Vif BC box A3Z2-Z3 (Bos taurus) [42, 43]
Unknown Unknown RhoB [44]
Page 4 of 11Cai and Yang  Cell Div  (2016) 11:7 
by PHDs, so it escaped recognition by VHL. As a conse-
quence it would accumulate, form HIF, and activate the 
transcriptional program to respond to hypoxia [8]. Any 
other conditions that disrupt the functions of PHDs or 
VHL will also lead to HIF stabilization and the activation 
of HIF pathway. In hereditary VHL disease, mutations 
and loss of heterozygosity (LOH) at the VHL locus in 
the cancer cells inactivates VHL and results in a consti-
tutively high level of HIFα even in the presence of oxy-
gen. The activated HIF targets can have opposing effects 
on tumor growth [54, 55], but the overall activity of the 
constitutively active HIF pathway is the major oncogenic 
force that drives tumorigenesis and tumor growth. It was 
known to cause many manifestation of VHL disease such 
as clear cell renal cell carcinoma, hemangioblastoma 
and pheochromocytoma [7], and the partial blockage of 
HIF pathway by anti-angiogenesis drugs produced sig-
nificant clinical benefits [56]. Currently, five drugs tar-
geting VEGFA (bevacizumab) or its receptors (sunitinib, 
sorafenib, pazopanib and axitinib) were approved by 
FDA for the treatment of renal cell carcinoma (RCC). The 
median survival of advanced RCC patients had increased 
from less than 1  year (receiving cytokine IFN-alpha) to 
nearly 2  year (receiving targeted therapies) during the 
last decade [57].
Although HIFα is the most studied VHL substrate and 
probably the most important one, CRL2VHL also recog-
nizes and mediates the degradation of many other sub-
strates. Similar to HIFα, Sprouty2 (Spry2), a protein that 
regulates cell migration and proliferation in response to a 
number of growth factors, was also hydroxylated by PHD 
at normoxia and recognized by VHL for degradation. 
Increased cellular level of Spry2 after silencing PHDs or 
VHL inhibited human fibroblast growth factor-elicited 
activation of ERK1/2 [58]. Rpb1 is the largest subunit of 
RNA polymerase II. It is also the enzymatic subunit of 
the complex, synthesizing cellular mRNAs [59]. Rpb1 
contains an LGQLAP motif that bears sequence and 
structural similarity to a VHL-binding sequence in 
HIF1α [60]. Similar to HIFα, the proline P1465 within 
the motif of Rpb1 was hydroxylated under oxidative 
stress [60]. Proline 1465 hydroxylation by PHD1 and 
the further recognition by VHL was required for oxida-
tive stress-induced Ser5 phosphorylation of Rpb1, the 
poly-ubiquitination of Rpb1 and the recruitment of Rpb1 
to the DNA, which stimulated formation of tumors by 
VHL+ cells [59]. In a different cell line, Rpb1 was poly-
ubiquitinated by VHL and degraded by proteasome [60]. 
Since the direct function of CRL2VHL was ubiquitination, 
the next fate of Rpb1 was probably determined by dif-
ferent cellular context. hsRPB7, another subunit of RNA 
polymerase II, was also reported to be poly-ubiquitinated 
by VHL and degraded. Consequently, VHL suppressed 
hsRPB7-dependent VEGF expression [61]. Atypical pro-
tein kinase C (PKC) is made up of two members, PKCλ/ι 
(PKCι is the human homologue of mouse PKCλ) and 
PKCζ. In other reports, both PKCλ and PKCζII (a rap-
idly degraded variant of PKCζ) were poly-ubiquitinated 
by VHL and degraded [62, 63]. Epidermal growth fac-
tor receptor (EGFR) was also reported to be a target of 
CRL2VHL. VHL limited EGFR signaling by promoting 
c-Cbl-independent poly-ubiquitination and  lysosome-
independent degradation of the activated EGFR [64]. In 
addition, some E3-ligase independent functions of VHL 
were reported [65–68]. In these cases, VHL interacted 
with other proteins, regulated their functions, but did 
not promote their poly-ubiquitination and degradation. 
For example, VHL bound to NF-kappa B agonist Card9, 
promoted its phosphorylation by CK2 and inhibited NF-
kappa B activity [64]. In particular, Lai et al. performed a 
series of proteomic analyses that identified many VHL-
interacting proteins [66]. It’s a valuable resource for fur-
ther investigation.
CRL2LRR‑1 complex
Leucine-Rich Repeat protein-1 (LRR-1) in worm was 
found to have a VHL box and functioned as a substrate 
recognition receptor in a CRL2 complex [16, 69]. In C. 
elegans, the CRL2LRR-1 complex degraded the Cip/Kip 
CDK-inhibitor CKI-1 in nucleus to ensure a proper 
G1-phase cell cycle progression in the germ cells [69–71]. 
In human cells, the orthologous human CRL2LRR1 com-
plex degraded the CDK-inhibitor p21Cip1, but did not 
regulate cell cycle because it only did so in the cytoplasm. 
Consequently, knockdown of Lrr1 resulted in increased 
cytoplasmic p21. This led to de-phosphorylation of cofi-
lin through the inhibition of Rho/ROCK/LIMK pathway. 
The de-phosphorylated cofilin activated actin cytoskel-
eton remodeling and promoted cell motility [69].
CUL2 was highly expressed in the germline and in 
early embryos in C. elegans [70]. In Drosophila mela-
nogaster, loss of function of CUL2 resulted in defects 
at the larval neuromuscular junction and aberrations 
in the development of female germ line [72]. Cul2 was 
also required to limit the number of motile cells in egg 
chambers [73] and for germline enclosure in testes [74]. 
Among several CRL2 complexes that were associated 
with germline development, CRL2LRR-1 complex was 
a critical one. LRR-1 null nematodes were defective in 
germ cell proliferation which resulted in animal steril-
ity. Similar phenotype was observed in CUL2 null ani-
mals [71]. Since LRR-1 null germ cells arrested at G2/M 
stage, it was tested whether suppression of the DNA 
replication checkpoint would rescue the phenotype. It 
was discovered that the suppression of CHK-1 (Chk1 in 
humans for checkpoint kinase 1) or ATL-1 (ATR, Ataxia 
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telangiectasia and Rad3 related) kinases, two core com-
ponents of the DNA replication checkpoint pathway [75, 
76], restored the fertility [71]. However, how LRR-1 or 
CUL2 deficiency caused hyper-activation of the DNA 
replication checkpoint pathway was still unknown. As 
CKI-1 suppression did not rescue the fertility phenotype 
of LRR-1 null animal, it was not the critical target for this 
phenotype [71].
In later steps of germ cell development, CRL2LRR-1 
regulated the balance between mitotic proliferation and 
meiotic entry. It was probably because CRL2LRR-1 could 
regulate the degradation of unidentified meiotic promot-
ing factors in the germline [77]. In nematode, CRL2LRR-1 
inhibited the first steps of meiotic prophase through reg-
ulating the stability of HORMA-domain protein HTP-3, 
a key protein for loading synaptonemal complex com-
ponents onto meiotic chromosomes [77]. Hence, CUL2 
played multiple roles in the development of the germline 
in nematodes. Since Cul2 is conserved in multi-cellular 
organisms [4], the regulation mechanisms of germline 
development may be similar in other organisms as well 
[77, 78].
CRL2FEM1B complex
Feminization-1 (FEM-1) was discovered to regulate 
apoptosis in the nematode sex determination pathway 
[79]. FEM-1 and its three homologs, Fem1a, Fem1b and 
Fem1c were found to contain a VHL-box, so theoretically 
they could interact with Cul2 [80]. Whereas FEM-1 and 
Fem1b were shown to target proteins for degradation, 
Fem1a and Fem1c were not confirmed as a component of 
CRL2 complex. In nematode, FEM-1 was found to target 
TRA-1 for ubiquitination [81]. TRA-1 was homologous 
to the mammalian Gli1 protein, an important transcrip-
tion factor in Hedgehog signaling. Consistent with the 
worm data, Fem1b promoted ubiquitination and sup-
pressed transcriptional activity of Gli1 in human [82]. 
Since Gli1 was an oncoprotein, Fem1b could be a tumor 
suppressor. Single nucleotide polymorphism (SNP) anal-
ysis revealed that Fem1b was associated with polycystic 
ovary syndrome [83]. In Fem1b-null mice insulin resist-
ance was observed [84]. It was also reported to mediate 
apoptosis in human colon cancer cells [85] and served as 
a biomarker in mouse colon cancer model [86]. Fem1a 
was also implicated in polycystic ovary syndrome [83] 
and sonic hedgehog pathway hyperactivation in cancer 
stem cells in gastric cancer [87].
Mouse Fem1b induced ubiquitin-mediated degrada-
tion of Ankrd37, a protein that was enriched in mouse 
testis [88]. In addition, mouse Fem1b interacted with 
the homeodomain protein Nkx3.1, which was a pivotal 
regulator of prostate development. Both Fem1b and 
Nkx3.1 null mice show similar defects in prostate ductal 
morphogenesis [89]. These data indicate that Fem1b plays 
a conserved role in the generation of sexual dimorphism.
CRL2PRAME complex
The human tumor antigen Preferentially Expressed Anti-
gen in Melanoma (Prame) was frequently overexpressed 
in various cancers, and the high level expression was usu-
ally correlated with advanced stages and poor clinical 
outcomes in a wide variety of cancers [90]. The consen-
sus LXXLL-binding domain at Prame‘s C terminus medi-
ated interaction with the retinoic acid receptor (RAR), 
and Prame acted as a dominant repressor of RAR sign-
aling and inhibited retinoic acid induced differentiation, 
growth arrest, and apoptosis [91]. At the N-terminus of 
Prame there was a VHL box, and it mediated the interac-
tion with Elongin C and Cul2. Genome-wide chromatin 
immunoprecipitation experiments revealed that Prame 
associated with the transcription factor NFY at enhancers 
and transcriptionally active promoters. In addition, CRL2 
complex were present together with Prame on chromatins 
[92]. Further analysis revealed that Prame interacted with 
OSGEP and LAGE3, two yeast proteins that were human 
orthologues of the ancient EKC/KEOPS complex. EKC/
KEOPS complex was shown to play a role in telomeres 
maintenance, transcriptional regulation, and t6A modifi-
cation of tRNAs [93, 94]. Furthermore, Prame recruited a 
CRL2 ubiquitin ligase to EKC complex on transcription-
ally active chromatin [95]. The substrates of the E3 ligase 
activity of CRL2PRAME complex are still unknown.
CRL2ZYG‑11 complex
ZYG-11 was identified as a gene that contributed to 
nematode zygote development in C. elegans [96]. Fur-
ther analysis revealed a VHL box at the N-terminus of 
ZYG-11, and it was shown to bind to Elongin C and form 
complex with Cul2 [97]. Although the substrate(s) of 
CRL2ZYG-11complex was not identified, genetic analysis 
revealed that the complex was required for many func-
tions of CUL2 in worm, such as the degradation of mater-
nal cyclin B [97]. ZYG-11 homologues are restricted to 
metazoan. C. elegans  has two ZYG11 family members, 
ZYG-11 and ZER-1. Both contain a VHL box and bind to 
Elongin C and CUL2. In human there are three ZYG11 
family members, Zyg11a, Zyg11b and Zyg11bl. Only 
Zyg11b and Zyg11bl contained a VHL box and bound to 
Elongin C and Cul2 [97]. In human, Zyg11bl was found 
to be highly expressed in skeletal muscle and the testes 
[98], and it was specifically expressed in the cytoplasm 
of late pachytene spermatocytes and the round sperma-
tids at meiotic division [98]. Although the substrate(s) 
was unknown, ZYG11 family members were proposed to 
function as substrate recognition receptors for CRL2 E3 
complexes in the metazoan lineage [97].
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CRL2BAF250 complex
Two isoforms of BAF250, BAF250a/ARID1A and 
BAF250b/ARID1B are defining components of human 
BAF complex. BAF complex and PBAF complex belong 
to SWI/SNF chromatin-remodeling complex, which 
remodels chromatin and facilitates DNA access by 
transcription factors and the transcription machinery 
[99]. Both BAF250a and BAF250b contained a BC box. 
BAF250b was shown to associate with Elongin B and C, 
Cul2 and Rbx1 to form an E3 ligase, which mono-ubiqui-
tinated histone H2B on lysine 120 site [100]. Konckdown 
of BAF250a or BAF250b decreased levels of global H2B 
ubiqitination in human cell line. In addition, the BAF250 
Drosophila homolog Osa mutant had reduced levels of 
mono-ubiquitinated H2B, and functioned synergistically 
with Cul2 in vivo [100]. These data suggest that BAF250 
has an evolutionarily conserved function to regulate H2B 
ubiqutination as a component of CRL2 E3 ligase to pro-
mote transcription.
CRL2RACK1 complex
The Receptor for Activated C Kinase 1 (Rack1), a mem-
ber of the tryptophan-aspartate repeat (WD-repeat) fam-
ily proteins, was found to bind the N-terminus of Fem1b 
and poly-ubiquitinated Fem1b for proteasomal degrada-
tion in colon cancer cells [101]. Rack1 was also reported 
to act as an E3 ligase component to degrade ΔNp63α, a 
member of the p53 family [102]. Through the WD40 
repeats, which contained an amino acid sequence simi-
lar to the VHL BC box, Rack1 was reported to bind to 
Elongin B and C and promoted the degradation of HIF1α 
in a HSP90-dependent but oxygen-independent manner 
[103]. In the presence of apoptotic agents, Rack1 medi-
ated the degradation of Bcl-2-interacting mediator of cell 
death extra long (BimEL) through a CRL2 E3 ligase com-
plex, and inhibited apoptosis in breast cancer cells [104]. 
The evidence suggests that Rack1 can be a component of 
CRL2 E3 complex and degrade target proteins via ubiqui-
tin–proteasome pathway.
A CRL2 complex targeting RhoB
Since neddylation on Cullins was required for the activ-
ity of CRL complexes [20–22], a small molecule inhibitor 
of NEDD8-activating enzyme, MLN4924, could induce 
the accumulation of CRL substrates that lead to DNA 
damage, cell cycle defects, senescence, apoptosis and 
autophagy [24, 105–107]. It was tested by several phase 
I clinical trials because of its significant anticancer activ-
ity and relatively low toxicity in preclinical analyses [108–
111]. A quantitative proteomic analysis identified RhoB 
as a target of CUL2-RBX1 complex [112]. The substrate-
recognition subunit was not identified in this study. RhoB 
is a small GTPase and a member of Rho family. It acts as 
a tumor suppressor and is frequently down-regulated in 
various cancers. The MLN4924-induced accumulation of 
RhoB seemed to contribute significantly to the antican-
cer activity of this drug in liver cancer. A caveat is that 
MLN4924 impacts on many targets, so it is difficult to 
pinpoint the contribution of CRL2 to cancer develop-
ment and treatment. Nonetheless, this highlights the 
potential therapeutic utility of targeting neddylation-
CRL2-RhoB in liver cancer and other cancers.
VHL box proteins
Several proteins have VHL box but were not confirmed 
as components of CRL2 complex. Their functions are 
summarized here, and their roles in CRL2 complex await 
further investigation.
Appbp2, the human homolog of Drosophila PAT1, also 
known as Ara67, was found to suppress androgen recep-
tor (AR) transactivation through interrupting AR cyto-
plasmic-nuclear shuttling [113]. Appbp2 was found to be 
overexpressed through 17q23 amplification in neuroblas-
toma [114], ovarian clear cell adenocarcinomas [115] and 
desmoplastic medulloblastomas [116].
Kelch domain containing 2 (Klhdc2), also known as 
Hclp1, could serve a transcriptional co-repressor through 
its inhibitory interaction with the Lzip transcription fac-
tor [117]. Klhdc3, also known as Peas, is evolutionarily 
conserved from nematodes to mammals. Mouse Peas 
was found to be expressed in testis, particularly in the 
cytoplasm and meiotic chromatin of pachytene spermat-
ocytes. It was suggested that Klhdc3 might be involved in 
the meiotic recombination process [118].
Zinc finger, SWIM-type containing 2 (Zswim2) was 
also known as MEKK1-related protein X (Mex), a testis-
expressed protein. It contained an N-terminal SWIM 
(SWI2/SNF2 and MuDR) domain and two RING fin-
gers separated by a ZZ zinc finger domain. Zswim2 was 
self-ubiquitinated as an E3 ubiquitin ligase and targeted 
for  degradation through the proteasome pathway [119]. 
The SWIM domain was found to be critical for Zswim2 
ubiquitination and was suggested to regulate death 
receptor-induced apoptosis in the testes. Zswim5 (also 
known as KIAA1511), Zswim6 and Zswim8 (also known 
as KIAA0913) all contained a VHL box and might play a 
similar role in E3 ligase complex, but this was not con-
firmed. Zswim5 displayed intense staining in gliomas but 
weak to modest staining in most other neoplasms [120]. 
Fyn-tyrosine-kinase-deficient mice had increased fearful-
ness and enhanced excitability. In the amygdala of Fyn-
deficient mice, only Zswim6 expression was significantly 
lowered after administration of N-methyl-D-aspartate 
(NMDA) when compared with that in Fyn-proficient 
mice, suggesting that it might be a key mediator of the 
phenotype [121]. Zswim6 mutations were associated with 
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acromelic frontonasal dysostosis, a rare disorder charac-
terized by the craniofacial, brain and limb malformations. 
Zswim6 mutations might lead to the phenotypes through 
the disruption of Hedgehog signaling [122].
Viral CRL2 E3 ligase complex
Viral infection activates host cell defense mechanisms, 
which will limit viral spread, inhibit viral replication and 
eliminate virus. Virus has developed various strategies to 
counter host cell defense and usurp the cellular machin-
ery. One strategy is that viral protein formed E3 ubiquitin 
ligase complex to destroy host proteins. Several viral pro-
teins that form CRL2 ligase complex had been reported 
to be indispensable for infection by adenovirus (Ad), 
Epstein–Barr virus (EBV), human papillomavirus (HPV) 
and bovine immunodeficiency virus (BIV).
Adenoviruses are linear double-stranded DNA viruses. 
They infect human and rodent cells, occasionally trans-
form them and cause tumors in animal models [123]. 
The human adenovirus type 5 (Ad5) early region 4 from 
open reading frame 6 (E4orf6) contained three BC boxes 
and formed an E3 ubiqutin ligase complex with Cullin 5 
(Cul5) [124, 125], whereas the human adenovirus type 
12 (Ad12), type 16 (Ad16), type 40 (Ad40) and type41 
(Ad41) formed complex with Cul2 [126, 127]. Adenovi-
ral protein E1B55K associated with the E4orf6 protein 
and recognized substrate to be degraded by ubiquitin–
proteasome pathway [124, 125]. In this complex, E4orf6 
was believed to recruit Cul2 or Cul5 as an adaptor pro-
tein, whereas E1B55K was believed to act as a substrate 
recognition receptor. As a result, the E1B55K-E4orf6-
Cul2 complex from different types of human adenovirus 
showed different substrate specificity against p53 [128, 
129], Mre11 [130], DNA ligase IV [131] and integrin 
α3 [126, 127, 132–135]. Among these substrates, DNA 
Ligase IV was the only universal substrate for all types of 
adenoviruses tested [126, 133]. In particular, Ad12 E4orf6 
not only recruited the Cul2 ubiquitin ligase complex but 
also acted as a substrate receptor for the ATR activator 
protein topoisomerase-IIβ–binding protein 1 (TOPBP1). 
Ad12 E4orf6 could inhibit the ATR-dependent phospho-
rylation of CHK1 through promoting the proteasomal 
degradation of TOPBP1 in the absence of E1B55K [133, 
136].
Epstein–Barr virus (EBV) is a human γ-herpesvirus, 
and it is able to induce several B cell and epithelial-cell 
malignancies. In viral life cycles, EBV periodically reac-
tivates and replicates in a lytic manner [137]. Induction 
of the EBV lytic program was found to trigger a cellular 
DNA damage response via activating the ATM-depend-
ent DNA damage signal transduction pathway [138]. This 
would induce apoptosis and limit viral replication by 
Chk2-mediated phosphorylation of p53 at its C-terminus 
[139, 140]. The EBV virus developed a method to circum-
vent this limitation. Bzlf1 protein of EBV had Cul2 and 
Cul5 boxes at its N-terminus and could form complexes 
with Cul2 and Cul5, and Bzlf1 recognized C-terminal 
phosphorylated p53 and induced p53 degradation to 
ensure efficient viral propagation [140, 141].
Human papillomaviruses (HPVs) are DNA viruses 
that specifically infect squamous epithelial cells Bernard 
HU2010. Among more than 120 different species identi-
fied so far, HPV16 was found in 50 % of cervical cancers 
[142]. E7 oncoprotein of HPV16 was necessary for the 
induction and maintenance of the oncogenic transforma-
tion [143]. HPV16 E7 was found to form a complex with 
Cul2 via an incomplete Cul2 box, and it bound and pro-
moted the degradation of a hypophosphorylated form of 
the retinoblastoma tumor suppressor (RB1) [144–146]. 
This allowed RB1–E2F complexes to dissociate and the 
G1-S phase transition to proceed, allowing the replica-
tion of the viral DNA in differentiated host cells [147, 
148]. In addition, Zyg-11 related cell cycle regulator 
(Zer1, also known as Zyg11bl) was required for the bind-
ing of HPV16 E7 to Cul2 and the destabilization of RB1 
in HPV16 E7-expressing cells [149].
The viral infectivity factor (Vif ) from human immuno-
deficiency virus type 1 (HIV-1) and simian immunodefi-
ciency virus (SIV) could form a CRL5 E3 ubiquitin ligase 
complex to degrade host antiviral APOBEC3 (A3) pro-
teins, so the HIV-1 could escape from A3-mediated host 
antiviral defense [150]. Similarly, Vif from bovine immu-
nodeficiency virus (BIV) interacted with Cul2, Elongin 
B/C and Rbx1, instead of Cul5 and Rbx2 in HIV, to form 
a CRL2 E3 ubiquitin ligase. This complex was reported 
to degrade the bovine A3 proteins (A3Z2Z3 and A3Z3) 
[104, 151]. Consistently, BIV Vif with mutations in the 
BC box or putative VHL box, which failed interact with 
Elongin B/C or Cul2, respectively, lost the ability to regu-
late bovine A3 proteins [104].
Conclusions
Among CRLs, Cul2 based E3 ligase complexes had a sim-
ilar structure and binding partners with Cul5 based E3 
ligase complexes, and both belonged to ECS family [3]. 
The substrate recognition receptor of Cul2 complex gen-
erally contained a VHL box, which contained a BC box 
and a Cullin box, and was very similar to SOCS box in 
Cul5 complex. Recent crystal structure analysis revealed 
the differences between CRL2 and CRL5 complexes, and 
indicated the possibility of fine-tuning CRL2 activity [17]. 
The activity of CRL2 can be regulated by neddylation on 
a key residue on Cul2 [24, 26]. Through various substrate 
receptors, CRL2 complexes recognize a number of sub-
strates and regulate their protein stability and function 
through polyubiquitination (Table 1). Defects in various 
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CRL2 complexes led to cancer and other human disease 
through abnormal stabilization and enhanced activity of 
their protein substrates. Inhibiting the activities of the 
substrates or those of their downstream effectors have 
shown clinical efficacy. As different viral proteins co-
opt Cul2 to evade host defense, inhibiting their activities 
might help us fight various viral infections. Thus through 
better understanding of the biology of CRL2 complexes, 
we can devise and develop new therapeutic strategies 
against cancers, inherited diseases and viral infections 
caused by dysregulated CRL2 complexes.
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